In this session, you will learn about key cost drivers in pharmacy trends, including but not limited to:
New high-cost drugs, including gene therapies, that treat rare and/or expensive conditions such as spinal muscular atrophy (SMA), inherited retinal disease, hemophilia A and B, Duchenne muscular dystrophy (DMD), sickle cell anemia and cerebral adrenoleukodystrophy (CALD).
Other cost drivers in the prescription drug category include the emergence of GLP-1s, digital therapeutics, targeted immunomodulators, accelerated approval drugs and expanded indications.
The implications of the end of the COVID-19 Public Health Emergency (PHE) on the costs of COVID-19 vaccines, testing and treatment claims.
Downward influences on pharmacy costs, such as the availability of new generic drugs and biosimilars.
Emerging trends in pharmacy benefits manager (PBM) contracting.
The initial portion of this discussion will be led by a pharmacist and former state pharmacy director. You will also hear a panel discussion compare and contrast how commercial plans, Medicare plans and Medicaid programs are navigating the challenges that these trends present and how they are expected to impact costs in each market segment. By attending this session, you will have a more complete understanding of how and why different market segments are expected to be impacted by the latest pharmacy trends and what payers and insurers in each market segment are doing to manage the impact of these trends.